Investigational drug · Phase 2
TRX103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Crohns Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "TRX103"
First trial start
2025
May 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRX103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Crohns Disease
Approved drugs for the same conditions: Crohn's disease · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "TRX103" as an intervention, largest first.
Tr1X, Inc.Industry
NCT06721962 · 39 participants (planned) · Start May 5, 2025 · Primary completion Jan 30, 2026
Drug: TRX103; Cyclophosphamide · For: Crohns Disease
Sites: Scottsdale, Arizona; Sacramento, California; San Francisco, California · 13 sites in all
Tr1X, Inc.Industry
NCT06462365 · 36 participants (planned) · Start Apr 8, 2024 · Primary completion Apr 15, 2026
Drug: TRX103 · For: Hematologic Malignancy; GvHD; GVHD,Acute and 8 more
Sites: Duarte, California; Boston, Massachusetts; Minneapolis, Minnesota · 5 sites in all
Quan Dong NguyenAcademic, hospital or other
NCT07427628 · 18 participants (planned) · Start Mar 18, 2026 · Primary completion Dec 2028
Drug: TRX103 · For: Non Infectious Uveitis
Sites: Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance.
Uyeda MJ, Re A, Tang C, et al. · Front Immunol 2026
Also in development for Crohns Disease
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.